GAITHERSBURG, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc. ALT, a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and nine months ended September 30, 2019 before the market opens and host a conference call on Thursday, November 14, 2019.
Conference Call Details | |
Date: | Thursday, November 14 |
Time: | 8:30 am Eastern Time |
Domestic: | 855-327-6837 |
International: | 631-891-4304 |
Conference ID: | 10008064 |
Webcast: | http://public.viavid.com/index.php?id=136942 |
About Altimmune
Altimmune is a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies. Our diverse pipeline includes next generation peptide therapeutics for NASH (ALT-801) and chronic Hepatitis B (HepTcellTM), conjugated immunostimulants for the treatment of cancer (ALT-702) and intranasal vaccines (NasoVAXTM and NasoShieldTM). For more information on Altimmune, please visit www.altimmune.com.
Contacts: | |
Will Brown Chief Financial Officer Phone: 240-654-1450 wbrown@altimmune.com | Ashley R. Robinson LifeSci Advisors, LLC 617-775-5956 arr@lifesciadvisors.com |
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.